Roche (RHHBY -0.7%) Innovation Center Basel's Dr. Adrian Roth presented results from a collaborative study with Organovo (ONVO +9.1%) scientists using the company's 3D Human Liver Tissues at the 3D Cell Culture 2014 conference in Freiburg, Germany yesterday. The study, conducted at Organovo, showed that the 3D Liver Model was able to distinguish a hepatotoxic drug from a close non-toxic chemical analog. The model detected the toxicity at physiologically relevant doses.
Organovo plans to launch the 3D Human Liver Tissue in late Q4 2014 as a testing service performed at Organovo's laboratory. This is a change in strategy considering it originally stated that it would sell the "assay" or "model" on-line as a deliverable product. The name change and service-only offering implies that the product is not as fully-developed as planned.